Matching articles for "COPD"
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • September 2, 2024; (Issue 1710)
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 2, 2024; (Issue 1710)
...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Ensifentrine (Ohtuvayre) for COPD
The Medical Letter on Drugs and Therapeutics • August 19, 2024; (Issue 1709)
The FDA has approved ensifentrine (Ohtuvayre –
Verona), an inhaled phosphodiesterase (PDE) 3 and
4 inhibitor, for maintenance treatment of chronic
obstructive pulmonary disease (COPD) in adults.
It is the...
The FDA has approved ensifentrine (Ohtuvayre –
Verona), an inhaled phosphodiesterase (PDE) 3 and
4 inhibitor, for maintenance treatment of chronic
obstructive pulmonary disease (COPD) in adults.
It is the first dual inhibitor of PDE3 and PDE4 to be
approved by the FDA, and the first inhaled drug
with a new mechanism of action to be approved for
treatment of COPD in more than 20 years.
Ryzneuta for Prevention of Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • August 19, 2024; (Issue 1709)
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a
nonpegylated granulocyte colony-stimulating factor
(G-CSF) conjugated to an Fc fragment of human
IgG2, has been approved by the FDA to decrease
the...
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a
nonpegylated granulocyte colony-stimulating factor
(G-CSF) conjugated to an Fc fragment of human
IgG2, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia. It is
the first nonpegylated, long-acting G-CSF to become
available in the US. Two pegylated, long-acting
G-CSFs, pegfilgrastim (Neulasta, and biosimilars)
and eflapegrastim (Rolvedon), are also available.
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Several...
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Several guidelines
and review articles on COPD treatment have been
published in recent years. Treatment of acute
exacerbations is not discussed here.
Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD
Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Table: Correct Use of Inhalers for COPD
Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD
In Brief: Respiratory Depression with Gabapentinoids
The Medical Letter on Drugs and Therapeutics • June 1, 2020; (Issue 1599)
The FDA has required new warnings in the labels of
gabapentin (Neurontin, and others) and pregabalin (Lyrica,
Lyrica CR, and generics) about the risk of life-threatening or
fatal respiratory depression in...
The FDA has required new warnings in the labels of
gabapentin (Neurontin, and others) and pregabalin (Lyrica,
Lyrica CR, and generics) about the risk of life-threatening or
fatal respiratory depression in patients with respiratory risk
factors. Respiratory risk factors include chronic obstructive
pulmonary disease (COPD) and concurrent use of opioids
or other CNS depressants. Elderly patients are also at
increased risk.
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • September 23, 2019; (Issue 1581)
The FDA has approved Duaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA)...
The FDA has approved Duaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA) formoterol
fumarate, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be
approved in the US for this indication.
Revefenacin (Yupelri) for COPD
The Medical Letter on Drugs and Therapeutics • January 28, 2019; (Issue 1564)
The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic
agent (LAMA) administered once daily by standard
jet nebulizer, for maintenance treatment of...
The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic
agent (LAMA) administered once daily by standard
jet nebulizer, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Revefenacin
is the second nebulized LAMA to be approved for this
indication; glycopyrrolate (Lonhala Magnair), which
is administered twice daily with a portable handheld
nebulizer, was the first.
Trelegy Ellipta - A Three-Drug Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • May 21, 2018; (Issue 1547)
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose
combination of the inhaled corticosteroid (ICS)
fluticasone furoate, the long-acting antimuscarinic
agent (LAMA) umeclidinium, and the...
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose
combination of the inhaled corticosteroid (ICS)
fluticasone furoate, the long-acting antimuscarinic
agent (LAMA) umeclidinium, and the long-acting
beta2-agonist (LABA) vilanterol. It is available as a dry
powder inhaler for once-daily maintenance treatment
of COPD and to reduce COPD exacerbations in patients
with a history of exacerbations. Trelegy Ellipta is
the first three-drug inhaler for treatment of COPD to
become available in the US.
Nebulized Glycopyrrolate (Lonhala Magnair) for COPD
The Medical Letter on Drugs and Therapeutics • April 23, 2018; (Issue 1545)
The FDA has approved an inhalation solution
formulation of the long-acting antimuscarinic agent
(LAMA) glycopyrrolate (Lonhala Magnair – Sunovion)
for maintenance treatment of chronic...
The FDA has approved an inhalation solution
formulation of the long-acting antimuscarinic agent
(LAMA) glycopyrrolate (Lonhala Magnair – Sunovion)
for maintenance treatment of chronic obstructive
pulmonary disease (COPD). The new formulation
is delivered using a portable, handheld, electronic
nebulizer. Glycopyrrolate is also available as a dry
powder inhaler, both alone (Seebri Neohaler) and in
combination with indacaterol (Utibron Neohaler),
and as a metered-dose inhaler in combination with
formoterol (Bevespi Aerosphere). Lonhala Magnair is
the first nebulized LAMA to become available in the US.
Comparison Table: Inhaled Short-Acting Bronchodilators for COPD (online only)
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
...
View the Comparison Table: Inhaled Short-Acting Bronchodilators for COPD
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Updated...
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Updated guidelines
for treatment of COPD have been published in
recent years.
Comparison Table: Inhaled Long-Acting Bronchodilators for COPD (online only)
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for COPD
Comparison Table: Some Inhaled Corticosteroids for COPD (online only)
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
...
View the Comparison Table: Some Inhaled Corticosteroids for COPD
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
...
View the Table: Correct Use of Inhalers for COPD
Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD
The Medical Letter on Drugs and Therapeutics • October 10, 2016; (Issue 1505)
The FDA has approved a fixed-dose combination of
the long-acting anticholinergic glycopyrrolate and
the long-acting beta2-adrenergic agonist (LABA)
formoterol (Bevespi Aerosphere – AstraZeneca)...
The FDA has approved a fixed-dose combination of
the long-acting anticholinergic glycopyrrolate and
the long-acting beta2-adrenergic agonist (LABA)
formoterol (Bevespi Aerosphere – AstraZeneca) for
long-term maintenance treatment of patients with
chronic obstructive pulmonary disease (COPD).
Glycopyrrolate/formoterol is the fourth long-acting
anticholinergic/LABA combination to be approved in
the US, but the first to become available in a metered-dose
inhaler. Glycopyrrolate/indacaterol (Utibron
Neohaler), umeclidinium/vilanterol (Anoro Ellipta),
and tiotropium/olodaterol (Stiolto Respimat) were
approved earlier.
Alternatives to Fluoroquinolones
The Medical Letter on Drugs and Therapeutics • June 6, 2016; (Issue 1496)
The FDA has announced that it is requiring changes in
the labeling of systemic fluoroquinolones to warn that
the risk of serious adverse effects, including tendinitis,
peripheral neuropathy and CNS effects,...
The FDA has announced that it is requiring changes in
the labeling of systemic fluoroquinolones to warn that
the risk of serious adverse effects, including tendinitis,
peripheral neuropathy and CNS effects, generally outweighs
their benefit for the treatment of acute sinusitis,
acute exacerbations of chronic bronchitis, and uncomplicated
urinary tract infections. For these infections, the
new labels will recommend reserving fluoroquinolones
for patients with no other treatment options.
Seebri Neohaler and Utibron Neohaler for COPD
The Medical Letter on Drugs and Therapeutics • March 28, 2016; (Issue 1491)
The FDA has approved two new inhalers for long-term
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Seebri Neohaler
(Novartis) contains the long-acting anticholinergic
glycopyrrolate....
The FDA has approved two new inhalers for long-term
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Seebri Neohaler
(Novartis) contains the long-acting anticholinergic
glycopyrrolate. Utibron Neohaler (Novartis) contains
both glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a
long-acting anticholinergic and a LABA to become
available in the US; umeclidinium/vilanterol (Anoro
Ellipta) and tiotropium/olodaterol (Stiolto Respimat)
were approved earlier.
Tiotropium/Olodaterol (Stiolto Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • November 23, 2015; (Issue 1482)
The FDA has approved a fixed-dose, orally inhaled
combination of the long-acting anticholinergic tiotropium
and the long-acting beta2-adrenergic agonist
olodaterol (Stiolto Respimat — Boehringer...
The FDA has approved a fixed-dose, orally inhaled
combination of the long-acting anticholinergic tiotropium
and the long-acting beta2-adrenergic agonist
olodaterol (Stiolto Respimat — Boehringer Ingelheim)
for long-term, once-daily, maintenance treatment of
airflow obstruction in chronic obstructive pulmonary
disease (COPD). It is not approved for treatment of acute
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)
and olodaterol (Striverdi Respimat) are also available
separately for once-daily treatment of COPD.
Fluticasone Furoate (Arnuity Ellipta) for Asthma
The Medical Letter on Drugs and Therapeutics • May 25, 2015; (Issue 1469)
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone...
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone furoate
is also available in combination with the long-acting
beta2-agonist vilanterol as Breo Ellipta for treatment
of asthma and COPD.
Umeclidinium (Incruse Ellipta) for COPD
The Medical Letter on Drugs and Therapeutics • April 27, 2015; (Issue 1467)
The FDA has approved Incruse Ellipta (GSK), a
single-agent inhaler containing the long-acting
anticholinergic umeclidinium, for once-daily maintenance
treatment of chronic obstructive pulmonary
disease...
The FDA has approved Incruse Ellipta (GSK), a
single-agent inhaler containing the long-acting
anticholinergic umeclidinium, for once-daily maintenance
treatment of chronic obstructive pulmonary
disease (COPD). Umeclidinium was initially approved
in combination with the long-acting beta2-adrenergic
agonist vilanterol as Anoro Ellipta.
Spiriva Respimat - An Oral Inhalation Spray for COPD
The Medical Letter on Drugs and Therapeutics • March 30, 2015; (Issue 1465)
Tiotropium bromide, an inhaled long-acting anticholinergic
available since 2004 as a dry powder inhaler
(Spiriva Handihaler) for once-daily treatment of chronic
obstructive pulmonary disease (COPD), has now...
Tiotropium bromide, an inhaled long-acting anticholinergic
available since 2004 as a dry powder inhaler
(Spiriva Handihaler) for once-daily treatment of chronic
obstructive pulmonary disease (COPD), has now also
been approved in an inhalation spray formulation
(Spiriva Respimat – Boehringer Ingelheim). According
to the manufacturer, the Respimat device improves
delivery of tiotropium to the lungs because, unlike with
the Handihaler, it is not dependent on the strength of
the patient’s breath intake.
Olodaterol (Striverdi Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • January 5, 2015; (Issue 1459)
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD). It is
not approved for treatment of acute exacerbations of
COPD or for treatment of asthma. Olodaterol is the third
long-acting beta2-agonist to be approved by the FDA
for once-daily use; indacaterol (Arcapta Neohaler),
which is available as a single agent, and vilanterol,
which is available only in fixed-dose combinations
with the long-acting anticholinergic umeclidinium
(Anoro Ellipta) or the corticosteroid fluticasone furoate
(Breo Ellipta), were approved earlier.
Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD
The Medical Letter on Drugs and Therapeutics • April 14, 2014; (Issue 1440)
The FDA has approved an inhaled fixed-dose
combination of the long-acting anticholinergic
umeclidinium (ue mek" li din' ee um) and the long-acting
beta2-adrenergic agonist (LABA) vilanterol
(Anoro Ellipta...
The FDA has approved an inhaled fixed-dose
combination of the long-acting anticholinergic
umeclidinium (ue mek" li din' ee um) and the long-acting
beta2-adrenergic agonist (LABA) vilanterol
(Anoro Ellipta – GSK/Theravance) for once-daily
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Anoro Ellipta is the first
product available in the US that combines two long-acting
bronchodilators in a single delivery device.
Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD
The Medical Letter on Drugs and Therapeutics • September 2, 2013; (Issue 1424)
The FDA has approved an inhaled fixed-dose combination
(Breo Ellipta – GSK/Theravance) of the corticosteroid
fluticasone furoate and the long-acting
beta2-adrenergic agonist (LABA) vilanterol...
The FDA has approved an inhaled fixed-dose combination
(Breo Ellipta – GSK/Theravance) of the corticosteroid
fluticasone furoate and the long-acting
beta2-adrenergic agonist (LABA) vilanterol trifenatate
for once-daily treatment of chronic obstructive pulmonary
disease (COPD).
Drugs for Asthma and COPD
The Medical Letter on Drugs and Therapeutics • August 1, 2013; (Issue 132)
INHALATION DEVICES — Metered-dose inhalers
(MDIs) require coordination of inhalation with hand-actuation
of the device. Valved holding chambers
(VHCs) or spacers help some patients, especially
young...
INHALATION DEVICES — Metered-dose inhalers
(MDIs) require coordination of inhalation with hand-actuation
of the device. Valved holding chambers
(VHCs) or spacers help some patients, especially
young children and the elderly, use MDIs effectively.
VHCs have one-way valves that prevent the patient
from exhaling into the device, minimizing the need for
coordinated actuation and inhalation. Spacers are
tubes or chambers placed between the canister and a
face mask or mouthpiece, which also avoids the need
to coordinate actuation and inhalation. Both VHCs
and spacers retain the larger particles emitted from the
MDI, decreasing their deposition in the oropharynx
and leading to a higher proportion of small respirable
particles being inhaled.
Indacaterol (Arcapta Neohaler) for COPD
The Medical Letter on Drugs and Therapeutics • April 30, 2012; (Issue 1389)
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with...
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Indacaterol is not approved for treatment of exacerbations of COPD or for treatment of asthma. It has been available in Europe as Onbrez Breezhaler since 2009.
Roflumilast (Daliresp) for COPD
The Medical Letter on Drugs and Therapeutics • July 25, 2011; (Issue 1369)
Roflumilast (Daliresp – Forest), an oral phosphodiesterase
4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients
with severe chronic obstructive pulmonary...
Roflumilast (Daliresp – Forest), an oral phosphodiesterase
4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients
with severe chronic obstructive pulmonary disease
(COPD) associated with chronic bronchitis and a history
of exacerbations.
Drugs for Chronic Obstructive Pulmonary Disease
The Medical Letter on Drugs and Therapeutics • November 1, 2010; (Issue 99)
The goals of drug therapy for chronic obstructive pulmonary
disease (COPD) are to reduce symptoms such
as dyspnea, improve exercise tolerance and quality of
life, and decrease complications of the disease...
The goals of drug therapy for chronic obstructive pulmonary
disease (COPD) are to reduce symptoms such
as dyspnea, improve exercise tolerance and quality of
life, and decrease complications of the disease such as
acute exacerbations. Other guidelines for treatment of
this condition have been published or updated in
recent years.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • September 1, 2010; (Issue 97)
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals...
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.
Safety of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)
The Medical Letter on Drugs and Therapeutics • May 31, 2010; (Issue 1339)
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the
FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and...
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the
FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol
(Symbicort). A Medical Letter reader has questioned the safety of using corticosteroid inhalers in patients
with this disorder. No single-agent inhaled corticosteroid inhaler is approved for this indication.
Drugs for Tobacco Dependence
The Medical Letter on Drugs and Therapeutics • September 1, 2008; (Issue 73)
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking...
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking cessation rates have been.
Formoterol (Perforomist) for COPD
The Medical Letter on Drugs and Therapeutics • November 19, 2007; (Issue 1274)
Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with...
Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana), the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.
Drugs for Chronic Obstructive Pulmonary Disease
The Medical Letter on Drugs and Therapeutics • November 1, 2007; (Issue 63)
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such...
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such as acute exacerbations and cor pulmonale. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines developed by the World Health Organization and the National Heart, Lung and Blood Institute were updated in 2006. The American Thoracic Society and the European Respiratory Society jointly developed guidelines for COPD in 2004.
Arformoterol (Brovana) for COPD
The Medical Letter on Drugs and Therapeutics • July 2, 2007; (Issue 1264)
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)
Tiotropium (Spiriva) for COPD
The Medical Letter on Drugs and Therapeutics • May 24, 2004; (Issue 1183)
Tiotropium bromide inhalation powder (Spiriva HandiHaler - Boehringer Ingelheim), a long-acting anticholinergic agent, has been approved by the FDA for once-daily maintenance treatment of bronchospasm...
Tiotropium bromide inhalation powder (Spiriva HandiHaler - Boehringer Ingelheim), a long-acting anticholinergic agent, has been approved by the FDA for once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). Available in Europe since 2002, it is the first long-acting inhaled anticholinergic drug for treatment of COPD. Ipratropium bromide (Atrovent), an anticholinergic used four times daily, has been available in the US for many years.